What is Wedbush's Forecast for argenx FY2026 Earnings?

argenx SE (NASDAQ:ARGX - Free Report) - Research analysts at Wedbush reduced their FY2026 EPS estimates for shares of argenx in a research note issued to investors on Wednesday, November 20th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $21.65 for the year, down from their prior estimate of $22.14. Wedbush has a "Outperform" rating and a $560.00 price objective on the stock. The consensus estimate for argenx's current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx's FY2027 earnings at $34.77 EPS.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the previous year, the business posted ($1.25) earnings per share.

Other analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft cut argenx from a "buy" rating to a "hold" rating in a research report on Friday, October 4th. Raymond James reiterated a "strong-buy" rating and issued a $605.00 price objective on shares of argenx in a research note on Thursday, October 10th. Truist Financial boosted their target price on shares of argenx from $540.00 to $660.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. upped their target price on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a report on Monday, November 4th. Finally, Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, argenx has an average rating of "Moderate Buy" and a consensus price target of $630.42.

argenx Stock Up 1.5 %

ARGX traded up $9.18 during mid-day trading on Friday, reaching $605.92. 363,516 shares of the company traded hands, compared to its average volume of 310,312. The stock has a market capitalization of $36.23 billion, a P/E ratio of -693.08 and a beta of 0.61. argenx has a 52-week low of $327.73 and a 52-week high of $611.22. The company's fifty day moving average price is $556.37 and its 200-day moving average price is $486.73.

Hedge Funds Weigh In On argenx

Hedge funds have recently added to or reduced their stakes in the stock. Profund Advisors LLC lifted its stake in argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock worth $418,000 after acquiring an additional 28 shares during the period. Raymond James Trust N.A. boosted its stake in shares of argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after purchasing an additional 28 shares in the last quarter. Wealth Alliance boosted its stake in shares of argenx by 4.8% during the second quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after purchasing an additional 29 shares in the last quarter. GAMMA Investing LLC raised its stake in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after buying an additional 40 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company's stock valued at $119,000 after acquiring an additional 43 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.